Navigation Links
Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Date:10/22/2008

tinued to increase throughout the 12-month treatment period. At the end of 12 months, Dimebon-treated patients were on average functioning as well or better than they had been at the start of the study on each of 5 clinical endpoints. These results were published in the July 19, 2008, edition of The Lancet.

In July 2008, Medivation announced positive safety and efficacy results from its Phase 2 trial of Dimebon in Huntington's disease. Dimebon appeared to be well tolerated and showed statistically significant benefit versus placebo in cognition as measured by the Mini-Mental State Examination, a secondary endpoint in the study.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
3. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
6. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
7. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
8. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
9. Medivation Announces Senior Management Promotions
10. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
11. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... University of Leicester has furthered our understanding of ... create new materials using nanosized ,building blocks,. , ... prestigious academic journal Physical Review Letters , ... rich detail the structure and internal atomic motion ... and a single helium atom. , The technique ...
(Date:7/25/2014)... WABC Radio show out of New York ... Young will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, ... in pets. Dr. Harman first visited the show in ... for pets suffering from osteoarthritis and other degenerative diseases, as ... forward. , Young has invited Dr. Harman back to dial ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), ... , today announced that it will release its unaudited ... after market close on Thursday, August 14, 2014 EDT. The ... opening on Friday, August 15, 2014, at 8:00 a.m. EDT ... to review the Company,s financial results and provide an update ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... , EAST BRUNSWICK, N.J., Sept. 8 Savient ... abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will ... in Philadelphia from October 16-21, 2009. The posters will be ... and include: , , , ...
... , CAMBRIDGE, Massachusetts, September 8 ... the global specialty biopharmaceutical company, is,committed to doing everything ... imiglucerase supply shortage. Shire is pleased to be,able to ... previously,anticipated commercial launch world wide. , ...
... , SAN DIEGO, Sept. 8 Biomatrica, Inc., the ... key appointments that will expand the breadth of leadership and commercial ... continued rapid growth in the development and commercialization of products for ... , Martin Latterich, Ph.D., has joined the company ...
Cached Biology Technology:Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4Update on velaglucerase alfa 2Update on velaglucerase alfa 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 5
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... (DTT), which is derived from diffusion tensor imaging ... tracts, such as the corticospinal tract, the rubrospinal ... corticospinal tract is known to be a major ... brain. Several studies have reported on injury of ... some studies have demonstrated recovery of a corticospinal ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... pressure were recently identified in a comprehensive international ... study, in which Uppsala University researchers participated, are ... Nature Genetics . High blood pressure ... Previous studies have shown that it is extremely ...
... May 8 Military and civilian personnel from the ... local homeland security, law enforcement and other first-responder personnel ... been encouraged to register and attend the 2009 Force ... held at Stafford Regional Airport and Marine Corps Base, ...
... and south sides of a house may decrease summertime ... a recent study* of California homes by researchers from ... the U.S. Department of Agriculture (USDA). The first ... the effects of shade on 460 single-family homes in ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2Demonstration Features Commercial Technology for Combating Terrorism 2New study: Home energy savings are made in the shade 2
Moue Serum 8-12 Weeks Old...
... is collected off the clot fasted non-Swiss Albino mice ... Available Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) ... CPD N-09: K3EDTA N-11: ...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: